Search Results - "Wolff, Debra"

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy by Lyman, Gary H., Kuderer, Nicole M., Crawford, Jeffrey, Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving…”
Get full text

Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review by LYMAN, Gary H, DALE, David C, WOLFF, Debra A, CULAKOVA, Eva, PONIEWIERSKI, Marek S, KUDERER, Nicole M, CRAWFORD, Jeffrey

“…To evaluate the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and overall mortality in patients receiving chemotherapy with or without…”
Get full text

Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens by GRIGGS, Jennifer J, CULAKOVA, Eva, SORBERO, Melony E. S, PONIEWIERSKI, Marek S, WOLFF, Debra A, CRAWFORD, Jeffrey, DALE, David C, LYMAN, Gary H

“…Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social…”
Get full text

Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice by Crawford, Jeffrey, Dale, David C, Kuderer, Nicole M, Culakova, Eva, Poniewierski, Marek S, Wolff, Debra, Lyman, Gary H

“…This study was undertaken to describe the relationship between the occurrence and timing of neutropenic events and chemotherapy treatment in a community-based…”
Get more information

Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy by GRIGGS, Jennifer J, CULAKOVA, Eva, SORBERO, Melony E. S, VAN RYN, Michelle, PONIEWIERSKI, Marek S, WOLFF, Debra A, CRAWFORD, Jeffrey, DALE, David C, LYMAN, Gary H

“…The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in…”
Get full text

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy by Shayne, Michelle, Culakova, Eva, Poniewierski, Marek S., Wolff, Debra, Dale, David C., Crawford, Jeffrey, Lyman, Gary H.

“…BACKGROUND. This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer…”
Get full text

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study by Culakova, Eva, Poniewierski, Marek S, Wolff, Debra A, Dale, David C, Crawford, Jeffrey, Lyman, Gary H

“…Background Febrile neutropenia (FN) is a major dose-limiting toxicity of cancer chemotherapy resulting in considerable morbidity, mortality, and cost. This…”
Get full text

Variation in the cost of medications for the treatment of colorectal cancer by Ferro, Salvatore A, Myer, Brian S, Wolff, Debra A, Poniewierski, Marek S, Culakova, Eva, Cosler, Leon E, Scarpace, Sarah L, Khorana, Alok A, Lyman, Gary H

“…To evaluate the economic burden of colorectal cancer (CRC) treatment on the healthcare system as treatment costs have risen 340-fold during the past 5 years…”
Get full text

Impact of a Rural Domestic Violence Prevention Campaign by Gadomski, Anne M., Tripp, Maria, Wolff, Debra A., Lewis, Carol, Jenkins, Paul

“…Domestic violence is a prevalent health problem that in rural areas is further complicated by limited services, social isolation and the lack of privacy…”
Get full text

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy by Shayne, Michelle, Culakova, Eva, Wolff, Debra, Poniewierski, Marek S., Dale, David C., Crawford, Jeffrey, Lyman, Gary H.

“…BACKGROUND: This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients…”
Get full text

Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis by Lyman, Gary H., Crawford, Jeffrey, Culakova, Eva, Poniewierski, Marek S., Wolff, Debra, Kuderer, Nicole M., Dale, David C.

“…Abstract 3100 Poster Board III-37 The risk of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS) is increased following prior exposure to cytotoxic…”
Get full text

Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy by Lyman, Gary H., Crawford, Jeffrey, Kuderer, Nicole M., Wolff, Debra, Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…Introduction: Neutropenic complications including severe neutropenia (SN) and febrile neutropenia (FN) represent major dose-limiting toxicities of cancer…”
Get full text

Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome by Lyman, Gary H., Dale, David C., Wolff, Debra, Culakova, Eva, Kuderer, Nicole M., Poniewierski, Marek S., Crawford, Jeffrey

“…Background: Retrospective studies have reported inconsistent results concerning risk of acute myeloid leukemia or myelodysplastic syndrome (t-ML) in cancer…”
Get full text

Registered Nurses Return to College: Lessons Learned from Hindsight by Wolff, Debra A

“…The recent impetus to increase the number of baccalaureate-prepared nurses comes from within and outside the profession, prompting increased numbers of…”
Get full text

A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients by Lyman, Gary H., Crawford, Jeffrey, Kuderer, Nicole M., Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…Anemia represents the most common hematological toxicity in cancer patients receiving systemic chemotherapy and is associated with considerable morbidity and…”
Get full text

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy by Shayne, Michelle, Culakova, Eva, Poniewierski, Marek S, Wolff, Debra, Dale, David C, Crawford, Jeffrey, Lyman, Gary H

“…BACKGROUND. This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer…”
Get full text

Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy by Lyman, Gary H., Dale, David C., Kuderer, Nicole M., Wolff, Debra A., Culakova, Eva, Poniewierski, Marek S., Crawford, Jeffrey

“…Anemia represents the most common hematological toxicity in cancer patients receiving chemotherapy and is associated with considerable morbidity and cost…”
Get full text

A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma by Lyman, Gary H., Crawford, Jeffrey, Wolff, Debra, Culakova, Eva, Poniewierski, Marek S., Dale, David C.

“…Background: Myelosuppression including severe and febrile neutropenia continues to represent a major cause of dose-limiting toxicity of cancer chemotherapy…”
Get full text

Changes in health care providers' knowledge, attitudes, beliefs, and behaviors regarding domestic violence, following a multifaceted intervention by Gadomski, A M, Wolff, D, Tripp, M, Lewis, C, Short, L M

“…To improve domestic violence (DV) identification, management, and referral in a not-for-profit rural health network, training for health care professionals was…”
Get full text

Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy by Shayne, Michelle, Culakova, Eva, Poniewierski, Marek S., Wolff, Debra, Dale, David C., Crawford, Jeffrey, Lyman, Gary H.

“…Introduction: Controlled clinical trials have provided limited data on hematologic toxicity and dose intensity of chemotherapy in the elderly. This study…”
Get full text